Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$1,055 Mln
Revenue (TTM)
$346 Mln
Net Profit (TTM)
$69 Mln
ROE
0.2 %
ROCE
-- %
P/E Ratio
16.9
P/B Ratio
2.8
Industry P/E
--
EV/EBITDA
-2.8
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$1
Face value
--
Shares outstanding
55,680,500
CFO
$-80.20 Mln
EBITDA
$-303.80 Mln
Net Profit
$-492.86 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Caredx Inc (CDNA)
| -11.8 | 11.4 | -2.3 | 34.3 | -7.7 | -11.1 | 11.5 |
|
BSE Sensex*
| 5.7 | 1.2 | 6.1 | 7.0 | 16.2 | 18.9 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Caredx Inc (CDNA)
| 77.6 | 5.2 | -74.9 | -37.2 | 235.9 | -14.2 | 240.2 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Caredx Inc (CDNA)
|
18.9 | 1,055.2 | 346.4 | 58.9 | -7.6 | 18 | 16.9 | 2.8 |
| 50.0 | 7,821.1 | 1,208.8 | 131.7 | 13.4 | 6.3 | 60.1 | 3.9 | |
| 128.3 | 8,303.1 | 562.1 | -155.7 | -19.3 | -47.5 | -- | 24.2 | |
| 148.4 | 7,238.7 | 4,022.6 | -31.6 | 3.7 | -1.1 | -- | 2.3 | |
| 51.2 | 9,911.0 | 2,828.1 | -1,019.8 | -36.2 | -36.4 | -- | 4.2 | |
| 45.7 | 11,827.4 | 2,298.9 | 643.6 | 35.4 | 29.2 | 19.8 | 5.2 | |
| 53.9 | 6,506.1 | 1,084.3 | 485.4 | 57.0 | 103.8 | 14 | 13.5 | |
| 315.3 | 8,891.5 | 2,156.6 | 416.4 | 21.2 | 56.5 | 23.6 | 15.0 | |
| 26.8 | 9,927.7 | 3,159.0 | -3,357.0 | -76.7 | -30.5 | -- | 1.0 | |
| 128.2 | 12,449.9 | 2,412.6 | 305.8 | 20.5 | 11.6 | 42.8 | 4.9 |
CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA)... solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI, a transplant quality tracking software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California. Address: 8000 Marina Boulevard, South San Francisco, CA, United States, 94005 Read more
CFO & Principal Accounting Officer
Mr. Abhishek Jain
CFO & Principal Accounting Officer
Mr. Abhishek Jain
Headquarters
South San Francisco, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Caredx Inc (CDNA) stood at $ 575 Mln as on 31-Mar-25
The share price of Caredx Inc (CDNA) is $18.88 (NASDAQ) as of 24-Jun-2025 16:00 EDT. Caredx Inc (CDNA) has given a return of -7.73% in the last 3 years.
Caredx Inc (CDNA) has a market capitalisation of $ 1,055 Mln as on 24-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Caredx Inc (CDNA) is 2.78 times as on 24-Jun-2025, a 0% discount to its peers’ median range of 2.79 times.
The P/E ratio of Caredx Inc (CDNA) is 16.92 times as on 24-Jun-2025.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Caredx Inc (CDNA) and enter the required number of quantities and click on buy to purchase the shares of Caredx Inc (CDNA).
CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI, a transplant quality tracking software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California. Address: 8000 Marina Boulevard, South San Francisco, CA, United States, 94005
The CEO & director of Mr. Abhishek Jain. is Caredx Inc (CDNA), and CFO & Sr. VP is Mr. Abhishek Jain.
There is no promoter pledging in Caredx Inc (CDNA).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,260
|
|
|
1,128
|
|
|
991
|
|
|
988
|
|
|
870
|
|
|
829
|
|
|
809
|
|
|
742
|
|
|
664
|
| Caredx Inc (CDNA) | Ratios |
|---|---|
|
Return on equity(%)
|
18.04
|
|
Operating margin(%)
|
-7.63
|
|
Net Margin(%)
|
16.99
|
|
Dividend yield(%)
|
--
|
Yes, TTM profit after tax of Caredx Inc (CDNA) was $69 Mln.
$-0.07
(
